Multimodality treatment with surgery in small-cell lung cancer

Area of Science:

• Oncology
• Thoracic Surgery
• Medical Oncology

Background:

• Small-cell lung cancer (SCLC) treatment often involves multimodal approaches.
• Surgery plays a role in the local treatment of primary SCLC.
• Optimizing adjuvant chemotherapy post-surgery is crucial for improving patient outcomes.

Purpose of the Study:

• To review the role of surgery in SCLC local treatment.
• To present preliminary results of a randomized trial comparing sequential intermittent polychemotherapy (sq CT) with standard chemotherapy (CT) after surgery for SCLC.
• To evaluate the safety and efficacy of sq CT in SCLC adjuvant therapy.

Main Methods:

• A multicentre, prospective, randomized cooperative trial was conducted.
• The trial compared sequential intermittent polychemotherapy (sq CT) (alternating drug combinations within one year post-surgery) with standard chemotherapy (CT) (one drug combination over three years post-surgery).
• Data from 56 patients (25 sq CT, 31 CT) were analyzed for survival rates up to February 1986.

Main Results:

• Sequential intermittent polychemotherapy (sq CT) was found to be applicable.
• No unexpected side effects were observed with sq CT.
• Five-year survival rates were improved in the sq CT group (36%) compared to the standard CT group (22%).

Conclusions:

• Sequential intermittent polychemotherapy (sq CT) demonstrates a survival benefit as an adjuvant treatment for SCLC after surgery.
• The observed safety profile of sq CT supports its use in clinical practice.
• These findings led to the design of a new, enlarged ISC-Study-Group protocol for further investigation.